Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma

Nature Reviews Clinical Oncology, Published online: 08 January 2024; doi:10.1038/s41571-023-00848-wDespite dramatic progress over the past decade, only around 50% of patients with advanced-stage melanoma derive durable benefit from immune-checkpoint inhibitors (ICIs) and/or BRAF and MEK (BRAF/MEK) inhibitors. Over the past few years, adoptive cell therapy with tumour-infiltrating lymphocytes (TILs) has demonstrated encouraging efficacy including in patients with disease progression on ICIs or BRAF/MEK inhibitors. In this Review, the authors summarize the role of TIL therapies in the management of these patients and describe future research strategies that might improve safety or efficacy.

Source: Nature Reviews Clinical Oncology - January 8, 2024 Category: Cancer & Oncology Authors: Sebastian Klobuch Tom T. P. Seijkens Ton N. Schumacher John B. A. G. Haanen Source Type: research